Headshot of Caterina Brindicci, Senior Vice President and Global Head of Respiratory & Immunology Late-Stage Development, BioPharmaceuticals R&D at AstraZeneca

As Global Head of Respiratory & Immunology Late-Stage Development, I work with experts across biometrics, regulatory affairs, clinical operations, and clinical development. Together, we advance potential medicines from phase IIb through to submission and approval, and subsequently into life cycle management.

Despite important advances in recent years, there continues to be significant unmet need across respiratory and immunology diseases – from conditions like asthma and COPD affecting millions across the globe, to rare diseases with limited treatment options.

I joined AstraZeneca in 2022 and have been struck by the outstanding commitment to pushing the boundaries of science to transform care for people living with respiratory and immunology-based diseases. It is our ambition to move beyond symptom management towards disease modification and remission. Science thrives in an environment of true collaboration, so I am so pleased to see the innovative partnerships at play, both within AstraZeneca and externally, to help us realise this ambition.

I have a steadfast commitment to patients and clinical excellence, and I am so proud to lead a global network of people dedicated to developing new respiratory and immunology medicines. I have a passion for supporting my teams and people to grow.

Caterina Brindicci Senior Vice President and Global Head of Respiratory & Immunology Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca
Headshot of Caterina Brindicci, Senior Vice President and Global Head of Respiratory & Immunology Late-Stage Development, BioPharmaceuticals R&D at AstraZeneca

CURRENT ROLE

Senior Vice President and Global Head of Respiratory & Immunology Lat-Stage Development, AstraZeneca

2022 - present: Senior Vice President and Global Head of Respiratory & Immunology Lat-Stage Development, AstraZeneca

Joined AstraZeneca as the Global Franchise Head for Inhaled Products

2020

Led the Respiratory & Allergy Development Unit at Novartis as the Clinical Development Head, following seven years of clinical development

2014

Global Clinical Program Head at Novartis

2010

Clinical Program Leader in Respiratory R&D at Chiesi

2007

Awarded PhD from Imperial College London in clinical pharmacology and molecular biology

Scientific publications

Veeva ID: Z4-51368
Date of preparation: December 2022